Credit Suisse 15/03/2010 1 Outperform $40.50 12.3%
Following news the company has received FDA approval for Hizentra the broker sees the subcutaneous immunoglobulin (SCIG) market the product is in as being worth as much as US$200m annually in sales.
It also notes the company has first mover advantage in the SCIG market, which should support margins in its view.
With the shares trading at a discount to their five-year average earnings multiple the broker retains its Outperform rating and $40.50 price target.
- Forums
- ASX - By Stock
- CSL
- credit suisse - $40.50
credit suisse - $40.50, page-24
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$308.92 |
Change
1.120(0.36%) |
Mkt cap ! $149.3B |
Open | High | Low | Value | Volume |
$310.21 | $311.38 | $308.47 | $89.69M | 289.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12971 | $339.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$278.03 | 9216 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 111 | 308.770 |
3 | 28 | 308.740 |
1 | 10 | 308.730 |
2 | 27 | 308.710 |
3 | 8 | 308.700 |
Price($) | Vol. | No. |
---|---|---|
308.780 | 28 | 6 |
308.790 | 298 | 10 |
308.800 | 417 | 5 |
308.810 | 28 | 2 |
308.820 | 84 | 6 |
Last trade - 15.59pm 20/08/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |